These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 17264340

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D.
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 5. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD.
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [Abstract] [Full Text] [Related]

  • 6. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [Abstract] [Full Text] [Related]

  • 7. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M.
    J Clin Oncol; 2007 Oct 01; 25(28):4466-71. PubMed ID: 17906207
    [Abstract] [Full Text] [Related]

  • 8. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M, Eisenhauer E.
    J Clin Oncol; 2004 Nov 15; 22(22):4595-603. PubMed ID: 15466785
    [Abstract] [Full Text] [Related]

  • 9. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.
    Gynecol Oncol; 2012 Jun 15; 125(3):621-4. PubMed ID: 22446622
    [Abstract] [Full Text] [Related]

  • 10. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF.
    Gynecol Oncol; 2000 Feb 15; 76(2):157-62. PubMed ID: 10637064
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM, Hyde J, Mannel RS, McMeekin DS, Moore KN, Walker JL.
    Gynecol Oncol; 2011 Sep 15; 122(3):527-31. PubMed ID: 21664657
    [Abstract] [Full Text] [Related]

  • 12. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
    McQuellon RP, Thaler HT, Cella D, Moore DH.
    Gynecol Oncol; 2006 May 15; 101(2):296-304. PubMed ID: 16376417
    [Abstract] [Full Text] [Related]

  • 13. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Monk BJ, Huang HQ, Cella D, Long HJ, Gynecologic Oncology Group Study.
    J Clin Oncol; 2005 Jul 20; 23(21):4617-25. PubMed ID: 15911864
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN, Pinto V, Rosen B, Oza A, Dodge J, Murphy J, Mackay H.
    Gynecol Oncol; 2009 Mar 20; 112(3):450-4. PubMed ID: 19135709
    [Abstract] [Full Text] [Related]

  • 16. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A, IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada.
    Gynecol Oncol; 2007 Jun 20; 105(3):747-56. PubMed ID: 17368522
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ, Braly P, Cecchi G, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Parker P, Stein A, Cho J, Smith E, Coluzzi P, Najera L, Johnson D, Womack E, Doroshow JH.
    Gynecol Oncol; 1999 Dec 20; 75(3):419-26. PubMed ID: 10600300
    [Abstract] [Full Text] [Related]

  • 18. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J.
    Gynecol Oncol; 2009 Apr 20; 113(1):63-7. PubMed ID: 19201457
    [Abstract] [Full Text] [Related]

  • 19. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C.
    Oncol Nurs Forum; 2004 May 20; 31(3):615-23. PubMed ID: 15146227
    [Abstract] [Full Text] [Related]

  • 20. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
    Richardson DL, Seamon LG, Carlson MJ, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE.
    Gynecol Oncol; 2008 Nov 20; 111(2):233-6. PubMed ID: 18768214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.